Search Medical Condition
Please enter condition
Please choose location from dropdown

Lyon Cedex 03, France Clinical Trials

A listing of Lyon Cedex 03, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (1063) clinical trials

Self-esteem and Neuro-urological Follow-up in Patients With Spina Bifida or Spinal Cord Injury

With improved life expectancy over the last fifty years, spina bifida has become a disease of the adult. The risk of developing a terminal renal insufficiency is eight times higher than the risk in the general population and twice as important as in acquired spinal cord injury. This risk continues ...

Phase N/A

0.0 miles

Learn More »

Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer (SHAPE)

At this time, it is not clear which of these approaches best balances the desire to prevent cancer of the cervix from returning with the risks of side effects after surgery and in the long-term.

Phase N/A

0.0 miles

Learn More »

Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification

After diagnosis of Neuroblastoma (NB) or Ganglioneuroblastoma : Frozen tumor sample (cell content 60%) must be sent for genomic profile determination by CGH-array, Blood sample at diagnosis must be sent to evaluate MYCN amplification in plasma, In case of NB with a MYCN amplification, blood sample during treatment and follow-up ...

Phase N/A

0.0 miles

Learn More »

D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma

A prospective, opened, multicentric, randomised, phase III trial with two arms: Arm A: curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin Arm B: curative gastrectomy with D1-D2 lymph node dissection Main objective: Compare overall 5-year survival rates in patients surgically treated for advanced gastric adenocarcinoma (T3, T4 ...

Phase

0.0 miles

Learn More »

Validation of the Quark RMR Calorimeter (Cosmed) Versus Deltatrac II (GE Health Care Clinical Systems)

Clinically, energy expenditure is usually estimated using predictive equations, such as the Harris-Benedict equation, which consider the patient's weight, height, age and sex to determine energy needs. However these have been shown to be unsystematically incorrect and may vary by 70-140% when compared with indirect and direct calorimetry measurements. That ...

Phase N/A

0.0 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

0.0 miles

Learn More »

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive Metastatic Medullary Thyroid Cancer

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate ...

Phase

0.0 miles

Learn More »

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order: STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with ...

Phase

0.0 miles

Learn More »

Ph II Cabazitaxel DD Liposarcoma

Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying patterns of tumor spread. The optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which ...

Phase

0.0 miles

Learn More »